Founder Group Targets Malaysia’s RM13–15 billion (approximately US$3.2 billion and US$3.7 billion) LSS6 National Solar Programme, Positioning for Multi-Year Order Book Growth Through 2029

KUALA LUMPUR, Malaysia, Sept. 02, 2026 (GLOBE NEWSWIRE) — Founder Group Limited (‘Founder Group’ or the ‘Company’) (NASDAQ: FGL) announced today that its subsidiary, Founder Energy Sdn. Bhd. (‘Founder Energy’), is actively tendering for projects under the Large-Scale Solar 6 (“LSS6”) programme, Malaysia’s largest-ever utility-scale solar tender. The Company believes LSS6 represents a multi-year growth opportunity that could progressively expand its order book from the current tender period through the programme’s targeted commercial operation date of December 31, 2029.

LSS6: Malaysia’s Largest Utility-Scale Solar Programme

The Ministry of Energy Transition and Water Transformation (PETRA) launched LSS6 in July 2026, offering a total quota of 2,500 megawatts (MW) of solar capacity paired with 1,250MW of battery energy storage system (BESS) capacity, together with a further 150MW of solar capacity reserved for Bumiputera companies in Peninsular Malaysia. PETRA has stated that the programme is expected to attract between RM13 billion and RM15 billion (between US$3.2 billion and US$3.7 billion) in private investment, with projects to be commissioned in phases and targeted to reach full commercial operation by December 31, 2029. As compared to previous LSS rounds, LSS6 is also the first LSS round to mandate hybrid solar-BESS development, and it translates into an engineering, procurement, construction and commissioning (EPCC) opportunity of comparable scale, the addressable market that Founder Energy is now tendering into.

Founder Energy’s Service Capabilities: Full-Suite EPCC & AI-Powered O&M

Founder Energy’s end-to-end EPCC capability is well matched to the LSS6’s scale, phased build-out, and multi-year construction runway, and the Company expects to see its order book growth progressively between now and the programme’s targeted commercial operation date as tender awards and construction packages are officially commerced.

Since inception, Founder Energy has been involved in over 70 solar EPCC and sub-EPCC projects across Peninsular Malaysia, spanning most of the phases of the government’s LSS programme since 2016, the Corporate Green Power Programme (CGPP), independent power producer (IPP) and Self-Consumption (SELCO) schemes, floating solar, and commercial and industrial (C&I) rooftop installations. Across its completed and on-going project base, Founder Energy has delivered work on facilities representing a combined total of over 1GWp of DC solar capacity, with an aggregate contract value of approximately RM520 million (US$128.6 million). Founder Group’s demonstrated ability to secure both direct EPCC awards, and sub-EPCC packages alongside established industry participants is a core competitive strength that it intends to leverage in pursuing LSS6 opportunities.

Beyond EPCC delivery, Founder Group also provides long-term asset lifecycle management. The Company integrates the proprietary AI-driven Operations & Maintenance (O&M) technologies. With LSS6 the first LSS round to mandate integrated BESS and a 2029 commercial operation horizon spanning decades of subsequent operation, the Company believes this O&M capability also positions it to capture recurring, long duration revenue that extends well beyond the construction phase into long-term asset management, complementing the project-based EPCC order book with a recurring, longer tail revenue stream.

CEO Commentary

“LSS6 is the largest solar tender Malaysia has ever launched, and it plays directly to our strengths as a full-capability EPCC provider. We are already active in the market, and our existing collaboration with leading Malaysian and International Solar companies who are best positioned to win LSS6 packages will directly benefit us through awards to be made over the next four years. Between these four years until LSS6 commissioned at the end of 2029, we are going to see us replenish our order book with new contracts and grow the business substantially,” said Lee Seng Chi, chief executive officer of Founder Group Limited.

Founder Group Limited Receives NASDAQ Notification Regarding Minimum Publicly Held Shares Deficiency

SELANGOR, Malaysia, Sept. 21, 2026 (GLOBE NEWSWIRE) — Founder Group Limited (Nasdaq: FGL) (“FGL” or the “Company”), announced today that on September 16, 2026, the Company received a letter from the Listing Qualifications Department of Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that since it no longer meets the minimum 500,000 publicly held shares requirement under Nasdaq Listing Rule 5550(a)(4) for the Nasdaq Capital Market, it no longer complies with the Listing Rules for continued listing.

The notification has no immediate effect on the listing or trading of the Company’s Class A ordinary shares. The Company has until November 2, 2026, to provide Nasdaq’s staff with a specific plan to achieve and sustain compliance with all The Nasdaq Capital Market listing requirements, including the time frame for completion of such plan. The Company intends to submit such plan within the required timeframe.

LG Electronics Kicks Off UAE Winter Roadshow for the All-New LG OLED EVO W6 Wallpaper TV

UAE residents can spot the ultra-thin 9 mm True Wireless OLED evo W6 at iconic destinations across the country, with interactive social contests and a chance to win the flagship television.

- LG Electronics is launching a winter-long roadshow across premier UAE destinations to showcase the all-new flagship LG OLED evo W6, True Wireless Wallpaper TV.

- The tour officially kicks off at The Lotus Lounge, Anantara The Palm Dubai Resort, running from 16 to 19 October 2026.

- Secret upcoming locations will be teased on Instagram via @lg_gulf. Guests who visit one of the spot and post an Instagram Story tagging #LGW6spotted and @lg_gulf will enter a grand draw to win an LG OLED W6 TV.

DUBAI, UAE, Oct. 17, 2026 /PRNewswire/ -- LG Electronics (LG) has announced the official launch of its nationwide UAE Winter Roadshow, showcasing the groundbreaking LG OLED evo W6, True Wireless Wallpaper TV. Commencing this weekend, the showcase will invite residents and visitors across the Emirates to experience the future of ultra-premium home entertainment firsthand in some of the country's most scenic and luxurious lifestyle venues.

The roadshow marks the regional debut of the LG OLED evo W6, True Wireless Wallpaper TV, celebrating the much-anticipated return of LG's iconic "Wallpaper" aesthetic. Measuring an ultra-slim 9.95mm in depth, the W6 mounts seamlessly flush against the wall with zero gaps, transforming the living space into a high-tech art gallery. Equipped with LG's proprietary Zero Connect wireless transmission technology, the screen delivers lossless 4K video and audio from an untethered AV box placed up to 10 meters away, completely eliminating visible cable clutter.

First Stop: The Lotus Lounge, Anantara The Palm Dubai Resort

The LG OLED evo W6 winter journey kicks off with an exclusive opening pop-up at The Lotus Lounge at Anantara The Palm Dubai Resort, running from 16 to 19 October 2026. Guests visiting the venue will see the display blending seamlessly into an upscale seaside hospitality environment.

A Gamified Winter Tour: #LGW6spotted

Throughout the winter season, the LG OLED evo W6 will pop up at surprise footfall lifestyle destinations across UAE.

To engage consumers and tech enthusiasts, LG Gulf is introducing an interactive social campaign:

- Ahead of every pop-up, upcoming secret locations will be teased on @lg_gulf on Instagram. Followers who correctly guess the venue can win exclusive on-the-spot giveaways.

- Visitors who embark on the city-wide trail and spot the installation at locations can enter a lucky draw to win their very own LG OLED evo W6, True Wireless Wallpaper TV at the conclusion of the campaign. To qualify, participants simply need to capture a photo of the TV, upload it to their Instagram Story, tag @lg_gulf, and use the hashtag # LGW6spotted.

Next-Generation Picture and AI Performance

Beneath its ultra-thin profile, the LG OLED evo W6 is driven by LG's most sophisticated brain yet: the α11 (Alpha 11) AI Processor 4K Gen3. Engineered to analyze content frame-by-frame, the processor utilizes deep learning to upscale imagery with astonishing spatial depth, refine facial realism, and map multi-channel virtual surround sound tailored to room acoustics.

Complementing the processor is LG's next-evolution Hyper Radiant Color technology alongside Brightness Booster Ultra, delivering luminous peak highlights that push conventional OLED boundaries while preserving the iconic inky, Perfect Blacks that define the medium. To suit the light-filled, open-plan spaces characteristic of modern homes in the region, the screen incorporates an advanced Reflection Free Premium coating that dramatically suppresses ambient glare without muting color vibrancy.

Setting an industry first, the LG OLED evo W6 also stands as the world's first True Wireless TV capable of transmitting 4K visual clarity at an ultra-smooth 165Hz refresh rate. Complete with full support for Dolby Vision, Dolby Atmos, and leading gaming technologies, including Variable Refresh Rate (VRR), NVIDIA G-Sync, and AMD FreeSync Premium, the LG OLED evo W6 ensures uncompromising performance whether playing host to high-octane gaming or an intimate, theater-grade cinema evening.

For more information about the LG OLED evo W6, visit:

https://www.lg.com/ae/tvs-soundbars/lg-oled83w66la. To follow the roadshow schedule, decipher location clues, and enter the contest, follow @lg_gulf on Instagram.

About LG Electronics Media Entertainment Solution Company

The LG Media Entertainment Solution Company (MS) is a recognized innovator in televisions, audio, displays and smart TV platforms. The MS Company enhances the media entertainment experience with its OLED TVs, renowned for perfect black and perfect color, and premium LCD QNED TVs, all powered by the personalized webOS smart TV platform. The MS Company also offers Information Technology solutions (gaming monitors, business monitors, laptops, projectors, cloud devices and medical displays) as well as Signage solutions (Micro LED signage, digital signage, hospitality displays and signage software solutions) that are designed to maximize customers' work efficiency and deliver strong value. For more news on LG, visit www.LGnewsroom.com.

SOURCE LG

Share this article

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Endava To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Endava between September 4, 2025 and September 21, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Oct. 17, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Endava plc ("Endava" or the "Company") (NYSE: DAVA) and reminds investors of the November 30, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) that the accounting treatment for certain customer and supplier agreements and related matters required additional review; (2) that, as a result of the foregoing, the Company would delay the release of its fourth quarter and full year 2026 financial results; (3) that there was reason to doubt the effectiveness of the Company's internal controls and procedures; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On September 21, 2026, after the market closed, Endava announced its Chief Financial Officer, Mark Thurston, was placed on administrative leave "upon the recommendation of the Company's Audit Committee of the Board." The decision was made "pending the conclusion of an ongoing investigation being conducted by independent outside counsel for the Committee, which was initiated in response to the Company's outside auditors raising concerns about the Company's accounting treatment of certain customer and supplier agreements and related matters."

On this news, the price of Endava's American Depositary Shares ("ADS") fell $0.68 per share, or 24.37%, to close at $2.11 per share on September 22, 2026, thereby injuring investors.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Endava's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Endava class action, go to www.faruqilaw.com/DAVA or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the Endava Securities Class Action Lawsuit:

What is the Endava securities fraud lawsuit about?

The lawsuit concerns Endava's accounting treatment of certain customer and supplier agreements, auditor-raised concerns, and the resulting investigation by independent outside counsel for the Audit Committee.

Who may be eligible to participate in the lawsuit?

Investors who purchased or acquired Endava plc (NASDAQ: DAVA) securities between September 4, 2025 and September 21, 2026 may be eligible if they suffered losses.

What is a lead plaintiff, and how can I seek appointment?

A lead plaintiff represents the proposed class during the litigation. Eligible investors must file a motion with the court by November 30, 2026. Investors may participate without serving as lead plaintiff.

Why should investors contact Faruqi & Faruqi, LLP?

Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Endava securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE Faruqi & Faruqi, LLP

Share this article

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Innventure To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Innventure between November 17, 2025 and August 13, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Oct. 17, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Innventure, Inc. ("Innventure" or the "Company") (NASDAQ: INV) and reminds investors of the October 27, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Accelsius' alleged transformative deal with DarkNX was unlikely to come to fruition as no evidence of DarkNX constructing or facilitating a large scale AI data center existed; (2) as a result, the Company's stated revenue and cash flow targets for Accelsius in 2026 were overstated; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On May 28, 2026, before the market opened, Morpheus Research published a report alleging that Innventure's DarkNX venture to build an AI data center campus in Ontario was a fabrication. The report revealed there was "zero evidence this project exists or that DarkNX has the team or funding to even contemplate such a project." Morpheus Research further reported that "[a]ccording to a former Innventure executive, management was using 'false information' and revenue projections that were 'pure fiction' to solicit investments into Accelsius." The report quoted multiple former Accelsius employees, who stated, among other things, "we've never heard of the company [DarkNX], they don't have customers, there's no data center."

On this news, Innventure's stock price fell $0.54 per share, or 8.42%, to close at $5.87 per share on May 28, 2026, on unusually heavy trading volume.

On August 13, 2026, after the market closed, Innventure reported second quarter 2026 results. Among other items, Innventure disclosed a net loss of $34.9 million, compared to $27.8 million in the first quarter of 2026, and an adjusted EBITDA loss of $22.6 million, compared to $18.4 million in the first quarter of 2026. The Company also announced it is "suspending [its] previously communicated expectations regarding Accelsius' 2026 revenue and cash flow targets and shifting [its] focus."

On the same day, Innventure filed its quarterly report on Form 10-Q with the SEC, disclosing that "the deployment site identified in the DarkNX purchase order is no longer available. Accelsius has removed the DarkNX project from its internal bookings."

On this news, Innventure's stock price fell $1.98 per share, or 55%, to close at $1.62 per share on August 14, 2026, on unusually heavy trading volume.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Innventure's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Innventure class action, go to www.faruqilaw.com/INV or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the Innventure Securities Class Action Lawsuit:

What is the Innventure securities fraud lawsuit about?

The lawsuit alleges that Innventure misled investors about Accelsius' proposed DarkNX AI data center project and overstated related 2026 revenue and cash flow expectations. Innventure later suspended those targets and disclosed that the DarkNX project had been removed from internal bookings.

Who may be eligible to participate in the lawsuit?

Investors who purchased or acquired Innventure (NASDAQ: INV) securities between November 17, 2025 and August 13, 2026 and suffered losses may be eligible to participate in the securities class action and should consider discussing their legal rights with counsel.

What is a lead plaintiff, and how can I seek appointment?

A lead plaintiff is an investor who represents the class and helps oversee the litigation on behalf of other investors. Innventure investors seeking appointment as lead plaintiff must file a motion with the court by October 27, 2026. Participation in any recovery does not require serving as lead plaintiff.

Why should investors contact Faruqi & Faruqi, LLP?

Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Innventure securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

Call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

SOURCE Faruqi & Faruqi, LLP

Share this article

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hyliion To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Hyliion between May 12, 2026 and June 23, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Oct. 17, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hyliion Holdings Corp. (""Hyliion" or the "Company") (NYSE: HYLN) and reminds investors of the October 27, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) in order to cause rapid price appreciation in Hyliion stock, Defendants announced a deal with an entity that was very recently formed and does not appear to have any actual business operations; (2) the Individual Defendants timed the announcement and foregoing price appreciation to insider trade; and (3) as a result, Defendants' statements about Hyliion's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On June 23, 2026, Pelican Way Research issued a report entitled "Hyliion: A Glorified Science Project Who Has Continuously Failed to Meet Expectations And Is Now Throwing Around A Meaningless Deal." On this news, Hyliion's stock price fell $1.27, or 17.2%, to close at $6.10 per share on June 23, 2026.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Hyliion's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Hyliion class action, go to www.faruqilaw.com/HYLN or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the Hyliion Securities Class Action Lawsuit:

What is the Hyliion securities fraud lawsuit about?

The lawsuit alleges that Hyliion Holdings Corp. and certain of its executives engaged in securities fraud during the class period by making materially false and misleading statements about the company's business, operations, and prospects. Specifically, the complaint allegedly asserts that Defendants announced a deal with a recently formed entity that does not appear to have any actual business operations, purportedly to cause rapid and artificial appreciation in Hyliion's stock price. The lawsuit further alleges that certain individual defendants timed the announcement and resulting price appreciation to engage in insider trading. On June 23, 2026, Pelican Way Research published a report critical of the company and its deal announcement, after which Hyliion's stock price allegedly fell $1.27 per share, or approximately 17.2%, to close at $6.10.

Who may be eligible to participate in the lawsuit?

Investors who purchased or otherwise acquired Hyliion Holdings Corp. (NYSE: HYLN) securities on the New York Stock Exchange between May 12, 2026 and June 23, 2026, inclusive, may be eligible to participate in this lawsuit. Eligible investors are not required to seek appointment as lead plaintiff in order to be considered a class member or to potentially share in any recovery that may be obtained. Class membership is open to all qualifying investors who suffered losses on their Hyliion holdings during the stated class period, subject to the outcome of the litigation. Investors who believe they may qualify are encouraged to review their trading records to determine whether their purchases fall within the applicable timeframe.

What is a lead plaintiff, and how can I seek appointment?

A lead plaintiff is a class member appointed by the court to act as the representative party on behalf of all class members in directing the litigation, including decisions regarding litigation strategy and the selection of lead counsel. Any investor who purchased Hyliion securities during the class period and suffered a loss may move for appointment as lead plaintiff, and the court generally appoints the movant with the largest financial interest in the relief sought who otherwise satisfies applicable legal requirements. The deadline to file a motion seeking appointment as lead plaintiff is October 27, 2026. Importantly, investors are not required to seek or serve as lead plaintiff in order to participate in the class action or to share in any recovery that the litigation may produce.

Why should investors contact Faruqi & Faruqi, LLP?

Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Hyliion securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

SOURCE Faruqi & Faruqi, LLP

Share this article

Industry-Leading Pulse Oximetry Platform Now Features First-of-Its-Kind Atrial Fibrillation (AFib) Detection with Previously Cleared AI-Enabled Opioid-Induced Respiratory Depression (OIRD) Detection Designed Together to Deliver Earlier Clinical Insights

IRVINE, Calif., Oct. 17, 2026 /PRNewswire/ -- Masimo, a Danaher company and a specialty diagnostics solutions innovator of pulse oximetry and other patient monitoring solutions, today announced FDA 510(k) clearance for AFib capability on Radius VSM®. Together with its previously cleared and AI-enabled OIRD detection capability, smartSET™ expands pulse oximetry beyond individual measurements, using advanced pattern recognition and AI signal analysis to help clinicians recognize physiological changes associated with important clinical events.

Building on the industry-leading Masimo Signal Extraction Technology (SET®) pulse oximetry and more than 35 years of signal-processing innovation, smartSET represents the next evolution of SET®, extending continuous monitoring from reliable measurement to clinical insight. Its AFib and AI-enabled OIRD capabilities help clinicians identify rhythms suggestive of AFib, and physiological patterns associated with OIRD to support earlier evaluation and intervention.

"When a patient deteriorates on a general care floor, respiratory compromise and cardiac arrhythmias often develop silently between routine rounds," said Dr. Basil Matta, Chief Medical Officer, Masimo. "By bringing AI-driven pattern recognition directly into the pulse oximetry workflow, smartSET helps clinicians see subtle physiological shifts earlier. It bridges the gap between spot checks, giving care teams actionable insight when minutes count."

"For more than three decades, Masimo has expanded what clinicians can expect from pulse oximetry," said Tim Benner, President, Masimo. "With smartSET, we are bringing intelligent sensing and AI-enabled detection to the bedside—building on our signal-processing expertise to turn continuous monitoring data into meaningful clinical insight. The addition of AFib monitoring to smartSET, alongside AI-enabled OIRD detection, represents a major leap forward to empower clinicians with earlier visibility into serious patient risks before symptoms escalate. Looking ahead, we intend to continue expanding the smartSET platform to address other critical clinical needs. This is how we advance innovation—by focusing on the information clinicians need to care for patients."

Recognizing Rhythms Suggestive of AFib

AFib affects more than 10% of patients over age 65 and often remains undiagnosed, significantly increasing the long-term risk of stroke1. The smartSET PPG AFib capability continuously analyzes pulse waveform data to identify rhythms suggestive of AFib, helping clinicians determine when additional electrocardiogram (ECG) or telemetry evaluation may be appropriate. The capability provides an indication for further clinical evaluation; it does not replace ECG confirmation of AFib.

In the clinical validation testing, the AFib capability demonstrated sensitivity and specificity of (97% and 100%, respectively).2 The study included cohorts with AFib and without AFib, including some with other arrhythmias. The study was conducted comparing the PPG AFib feature classifications against those made by 3 different clinicians reviewing the concurrently collected ECG strips as the ground truth for an AFib classification.

Helping Clinicians Recognize and Respond to OIRD

1 in 10 surgical patients receiving opioids experience an opioid-related adverse event3, while 85% of postoperative OIRD events occur within the first 24 hours after surgery4. Continuous monitoring helps address the gaps between routine spot checks; however, identifying OIRD can still depend on recognizing concerning trends in the data. The smartSET OIRD capability continuously analyzes oxygen saturation (SpO₂), pulse rate (PR), and perfusion index (Pi) in real time to assess opioid overdose risk. By identifying patterns associated with OIRD, the system generates escalating notifications on Radius VSM and is designed to provide clinicians with peace of mind.

From Signal Processing to Clinical Insight

With AFib and OIRD capabilities available within a traditional pulse oximetry workflow, smartSET expands the clinical information clinicians can obtain from continuous pulse oximetry monitoring by moving beyond individual measurements to automated detection, helping clinicians identify clinically relevant patterns.

Healthcare organizations interested in learning more or scheduling an evaluation can visit the smartSET webpage or contact their Masimo representative.

References

- Turakhia MP et al. PloS One. 2018;13(4):e0195088.

- Masimo data on file.

- Shafi S et al. JAMA Surg. 2018;153(8):757-763.

- Gupta K et al. BMJ Open. 2018;8(12).

Masimo PPG AFib feature is FDA cleared to identify rhythms suggestive of atrial fibrillation (AFib) over a monitoring period to supplement the decision for AFib screening in patients 18 years or older. The feature is not intended to replace traditional methods of diagnosis or treatment.

About Masimo

Masimo, a Danaher company and a specialty diagnostics solutions innovator of pulse oximetry and other patient monitoring solutions, develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is for our innovations to empower clinicians to transform patient care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown to outperform other pulse oximetry technologies in over 100 independent and objective studies, which can be found at www.masimo.com/evidence/featured-studies/feature. Masimo SET® is estimated to be used on more than 200 million patients around the world each year and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2026 Newsweek World's Best Hospitals listing. Additional information about Masimo and its products may be found at www.masimo.com.

About Danaher

Danaher is a leading global life sciences and diagnostics innovator, committed to advancing the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve many of their most complex scientific and clinical challenges—accelerating the moment scientific discovery becomes human impact. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. That's Innovation at the speed of life. Explore more at www.danaher.com.

Media Contact:

Ilke Limoncu

Vice President, Communications

Danaher, Diagnostics

[email protected]

SOURCE Masimo Corporation

Share this article

JinkoSolar Unveils Tiger Neo 5.0 All-Black Residential Solar Module with 25.52% Efficiency

SHANGRAO, China, Oct. 17, 2026 /PRNewswire/ -- JinkoSolar Holding Co., Ltd. ("JinkoSolar" or the "Company") (NYSE: JKS), today unveiled Tiger Neo 5.0, an all-black residential solar module built on its all-new TAC technology. The first version to reach the market, an all-black 48-cell module, delivers a maximum power output of 510 W with a module efficiency of 25.52%. It was designed to redefine the upper limits of what a scenario-specific module can deliver in both appearance and efficiency for premium homes and other architecturally refined residences.

The module showcases a deeper, more uniform and more refined black appearance than conventional back-contact (BC) modules. Semiconductor-grade low- and high-temperature processes bring the power temperature coefficient down to -0.24%/℃, meaning stronger energy yield in high-temperature environments.

TAC technology combines the excellent carrier transport of TOPCon with the low-temperature processing and positive electrode passivation of HJT, pushing peak cell efficiency to 28%, approaching the theoretical limit of monocrystalline silicon cells. Together with a zero-gap cell layout and hidden-ribbon technology at module level, the module achieves an efficiency of 25.52%. Compared with conventional BC products, it delivers approximately 30 W more power, and a lower temperature coefficient. Its deeper, more premium black appearance blends seamlessly into residential rooftops— especially dark-colored ones — making it a standout in the residential module category for both power and aesthetics.

"Our vision for Tiger Neo 5.0 was to develop a panel tailored to premium residential rooftops. It pushes the boundaries of both performance and aesthetics with innovations in cell technology, passivation processes, structural design, module format and interconnections. With this launch, we aim to help move the industry toward solutions tailored to specific applications," said Charlie Cao, CEO of Jinko Solar Co., Ltd.

About JinkoSolar Holding Co., Ltd.

JinkoSolar (NYSE: JKS) is a holding company combining clean energy industrial operations and strategic investment in emerging technologies. Its industrial foundation is a controlling interest in Jinko Solar Co., Ltd. (SSE: 688223), a global leader in clean energy technology. The Company makes disciplined strategic investments in renewable energy, advanced materials, artificial intelligence, commercial space and other frontier technologies, drawing on its industrial experience and its ability to identify emerging technologies and bring them to commercial scale.

Through Jinko Solar Co., Ltd., the Company distributes its solar products and sells its solutions and services to a diversified international utility, commercial and residential customer base in China, the United States, Japan, Germany, the United Kingdom, Chile, South Africa, India, Mexico, Brazil, the United Arab Emirates, Italy, Spain, France, Belgium, Netherlands, Poland, Austria, Switzerland, Greece and other countries and regions.

JinkoSolar has over 10 production facilities globally, over 20 overseas subsidiaries in Japan, South Korea, Vietnam, India, Turkey, Germany, Italy, Switzerland, the United States, Mexico, and other countries, and a global sales network with sales teams in China, the United States, Canada, Brazil, Chile, Mexico, Italy, Germany, Turkey, Spain, Japan, the United Arab Emirates, Netherlands, Vietnam and India, as of June 30, 2026.

To find out more, please see: www.jinkosolar.com

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the quotations from management in this press release and the Company's operations and business outlook, contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in JinkoSolar's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. Except as required by law, the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

For investor and media inquiries, please contact:

Ms. Stella Wang

JinkoSolar Holding Co., Ltd.

Tel: +86 21-5180-8777 ext.7806

Email: [email protected]

SOURCE JinkoSolar Holding Co., Ltd.

Share this article

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In XTI Aerospace To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in XTI Aerospace between April 15, 2026 and August 17, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Oct. 17, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against XTI Aerospace, Inc. (""XTI Aerospace" or the "Company") (NASDAQ: XTIA) and reminds investors of the October 27, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) that senior executives had engaged in certain undisclosed activities; (2) that these activities required Board review; (3) that there was reason to doubt the effectiveness of the Company's disclosure controls and procedures; (4) that, as a result, the Company would be unable to timely file its earnings reports; and (5) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On August 17, 2026, after the market closed, XTI Aerospace revealed that it could not timely file its Form 10-Q because it is "in the process of completing an internal review of the Registrant's former Chief Executive Officer, who resigned on August 17, 2026, and other related corporate governance matters." On this news, XTI Aerospace's stock price fell $0.25, or 15.9%, to close at $1.32 per share on August 18, 2026, on unusually heavy trading volume.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding XTI Aerospace's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the XTI Aerospace class action, go to www.faruqilaw.com/XTIA or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the XTI Aerospace Securities Class Action Lawsuit:

What is the XTI Aerospace securities fraud lawsuit about?

Faruqi & Faruqi, LLP has filed a securities class action lawsuit against XTI Aerospace, Inc. (NASDAQ: XTIA) on behalf of investors who purchased shares during the Class Period. The complaint alleges that senior executives allegedly engaged in certain undisclosed activities that required Board review and that the Company's disclosure controls and procedures were allegedly ineffective. As a result, the lawsuit alleges, XTI Aerospace was unable to timely file its earnings reports, and Defendants' positive statements about the Company's business, operations, and prospects were allegedly materially misleading and/or lacked a reasonable basis. The alleged misconduct came to light on August 17, 2026, when XTI Aerospace disclosed after market close that it could not timely file its Form 10-Q due to an ongoing internal review of its former Chief Executive Officer, who resigned that same day, and related corporate governance matters. On this news, XTI Aerospace's stock price allegedly declined $0.25, or approximately 15.9%, to close at $1.32 per share on August 18, 2026, on unusually heavy trading volume.

Who may be eligible to participate in the lawsuit?

Investors who purchased or otherwise acquired XTI Aerospace, Inc. (NASDAQ: XTIA) shares on the NASDAQ exchange between April 15, 2026 and August 17, 2026, inclusive, may be eligible to participate in this class action lawsuit. Eligibility to participate is not limited to those who apply to serve as lead plaintiff; any class member who purchased shares during the Class Period may potentially share in any recovery obtained. Investors are encouraged to review their trading records to determine whether their purchases fall within the defined Class Period. Those with questions about their eligibility are encouraged to consult with counsel to evaluate their options.

What is a lead plaintiff, and how can I seek appointment?

A lead plaintiff is a court-appointed representative who acts on behalf of all class members in directing the litigation, including making key decisions about case strategy and settlement. Any investor who purchased XTI Aerospace shares during the Class Period may move the court for appointment as lead plaintiff, and the deadline to file such a motion is the lead plaintiff deadline in this matter. Courts generally appoint the movant with the largest financial interest in the case who otherwise satisfies applicable legal requirements as lead plaintiff. Importantly, investors are not required to seek appointment as lead plaintiff in order to be eligible to share in any recovery that may result from the lawsuit. Class members who do not serve as lead plaintiff may still participate in any settlement or judgment obtained on behalf of the class.

Why should investors contact Faruqi & Faruqi, LLP?

Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased XTI Aerospace securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In XTI Aerospace To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in XTI Aerospace between April 15, 2026 and August 17, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

SOURCE Faruqi & Faruqi, LLP

Share this article

SHANGHAI, Oct. 17, 2026 /PRNewswire/ -- Vivacta Biotechnology (Shanghai) Co., Ltd. ("Vivacta Bio"), a company spun out of the in vivo CAR-T platform of Beijing Grit Biotherapeutics Co., Ltd. ("Grit Bio"), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to GT801, Vivacta Bio's lead investigational product, for the treatment of autoimmune hemolytic anemia (AIHA). The designation marks an important step in GT801's development for autoimmune diseases and enables potential access to incentives supporting GT801's further development in AIHA in the United States.

Addressing Unmet Need in AIHA Through B Cell Targeting

AIHA is an autoimmune disorder characterized by excessive, autoantibody-mediated destruction of red blood cells. Symptoms may include anemia, fatigue and shortness of breath, and severe cases can be life-threatening. Some patients continue to experience inadequate disease control despite multiple lines of therapy, underscoring the need for new treatment options.[1,2]

Recent clinical investigations of CD19 CAR-T in refractory AIHA have opened a new treatment avenue through B-cell depletion. Simplifying treatment and improving access, while continuing to evaluate safety and efficacy, remain key areas for further development.[2]

Early Clinical Activity Supports Development in Autoimmune Diseases

GT801 is an investigational in vivo CAR-T therapy that combines mRNA with T-cell-targeted lipid nanoparticle (LNP) delivery technology. By delivering mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) into patients' T cells, GT801 is designed to generate CAR-T cells directly in the body to recognize and eliminate CD19-positive B cells.

Preliminary clinical results for GT801 in patients with autoimmune diseases were presented in a poster at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. Two patients with AIHA both achieved complete response (CR) following GT801 treatment. One patient achieved CR at Week 4 and remained in CR at the Week 8 and Month 3 assessments; the other achieved CR at Week 10. Sustained peripheral B-cell depletion was also observed, together with increased hemoglobin levels and reductions in lactate dehydrogenase, indirect bilirubin and reticulocyte counts. These preliminary findings indicated promising clinical prospect of GT801 in AIHA.[3]

FDA Orphan Drug Designation Supports GT801's Global Development

Orphan Drug Designation is intended to encourage the development of treatments for rare diseases. Subject to applicable requirements, sponsors of designated products may be eligible for incentives including tax credits for qualified clinical trial expenses, exemption from marketing application user fees, and the potential for seven years of orphan drug market exclusivity following marketing approval.[4]

"GT801's Orphan Drug Designation is an important milestone in the project's global development in autoimmune diseases. It also reflected continued progress in advancing therapies originated from Grit Bio's in vivo CAR-T platform, particularly in rare autoimmune diseases," said Yarong Liu, Ph.D., Founder, Chairperson and Chief Executive Officer of Grit Bio. "Grit Bio and Vivacta Bio will continue to advance research and clinical translation guided by patient needs, build a stronger body of clinical evidence, and make innovative treatment options more accessible to patients."

About Vivacta Bio

Vivacta Bio is a biotechnology company focused on in vivo CAR-T innovation, with the aim of advancing transformative therapies in oncology and autoimmune diseases. Established on June 25, 2025, the company was spun out of Grit Bio's in vivo CAR-T platform. Its therapies use targeted LNP delivery to express CAR directly in patients' T cells, offering a new approach to treating hematologic malignancies and autoimmune diseases. This approach also eliminates the need for cell isolation, ex vivo expansion and lymphodepletion. By addressing the high costs, lengthy treatment timelines and toxicity associated with such processes, Vivacta Bio's platform has the potential to broaden patient access. Its lead candidate, GT801, has shown promising potentials in hematologic malignancies and autoimmune diseases.

About GT801

GT801 is an investigational anti-CD19 in vivo CAR-T therapy based on T-cell-targeted LNP technology. The product combines ionizable cationic lipids with CLAMP technology platform, featuring a distinctive T-cell-targeting VHH antibody, site-specific conjugation, and precisely controlled ligand density. The design enhances T cell targeting efficiency while minimizing nonspecific uptake, enabling efficient CAR expression in vivo. GT801 is engineered to generate potent, durable CAR-T cells within the patient and to support repeat dosing. With low cost, strong therapeutic activity and ease of administration, GT801 aims to address challenges in manufacturing economics and production timelines that constrain the commercialization of ex vivo cell therapies.

References

[1] MedlinePlus. Immune hemolytic anemia. https://medlineplus.gov/ency/article/000576.htm

[2] Li R, et al. CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia. N Engl J Med. 2026;394:253–267. doi:10.1056/NEJMoa2509820.

[3] Sun J, Zhu X, Jin J, et al. Targeted mRNA-LNP Delivery Enables In Vivo CAR-T Generation by GT801 with Potent B-Cell Depletion in Humans. Poster presented at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting.

[4] U.S. Food and Drug Administration. Designating an Orphan Product: Drugs and Biological Products. https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products

Vivacta Contact

Yanwen Zhang

Email: [email protected]

Telephone: +86-21-50828029

SOURCE Vivacta Bio

Share this article